<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330330</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 113715-CS7</org_study_id>
    <nct_id>NCT00330330</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 in Patients With Type 2 Diabetes Mellitus Who Have Not Received Prior Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five
      ISIS 113715 intravenous dose cohorts in drug-na√Øve type 2 diabetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of ISIS 113715</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profile of ISIS 113715</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacologic activity of ISIS 113715</measure>
  </primary_outcome>
  <enrollment>96</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 113715</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus of less than 5 years in duration

          -  Have never received hypoglycemic therapy

          -  Aged 18 to 65 years

          -  Fasting blood glucose between 130 and 220 mg/dL (7.2 to 12.2 mmol/L) for Cohorts A-D
             and between 140 and 220 mg/dL (7.8 to 12.2 mmol/L) for Cohort E

          -  HbA1c between 6.8 and 10.0% for Cohorts A-D and between 7.5 and 11.0% for Cohort E

          -  Body Mass index &gt; 25 and &lt; 35 kg m -2

        Exclusion Criteria:

          -  Medication that may affect glucose homeostasis (e.g. systemic glucocorticoid) within
             one month of screening

          -  Clinically significant abnormalities in medical history or physical exam

          -  Clinically significant abnormalities on laboratory examination

          -  History of HIV infection

          -  Active infection requiring antiviral or antimicrobial therapy

          -  Malignancy (with the exception of basal or squamous cell carcinoma of the skin if
             adequately treated and no recurrence for &gt; one year at the time of screening)

          -  Any other concurrent condition which, in the opinion of the Investigator, would
             preclude participation in or interfere with compliance

          -  Alcohol or drug abuse

          -  Undergoing or have undergone treatment with another investigational drug, biologic
             agent or device within 90 days of screening

          -  Abnormal serum creatinine concentration defined as &gt; 1.5 mg/dL (132.6 micro mol/L) for
             males and &gt; 1.2 mg/dL (106 micro mol/L) for females

          -  Medications that may affect coagulation (heparin, warfarin, etc.) with the exception
             of acetylsalicylic acid or non-steroidal anti-inflammatory agents.

          -  Allergy to sulfur-containing medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark K Wedel, MD, JD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Ionis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny</name>
      <address>
        <city>Bialystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska</name>
      <address>
        <city>Radom</city>
        <zip>26-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chorob Wewnetrznych ze Stacja Dializ Szpital w Wolominie</name>
      <address>
        <city>Wolomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Endocrinology and Diabetology of the Faculty of Advenced Training for Physicians</name>
      <address>
        <city>Moscow</city>
        <zip>109125</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Scientific Centre of RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Institution &quot;Polyclinic OAOA Gazprom&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117420</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Close Corporation &quot;MEDSI&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Endocrinology and Diabetology Central Clinical Hospital of the Ministry of Communications of RF</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Scientific-Research Clinical Institute named after I.F. Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Therapy of Postgraduate Education named after N.S. Molchanov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <last_update_submitted>February 4, 2008</last_update_submitted>
  <last_update_submitted_qc>February 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2008</last_update_posted>
  <keyword>Fasting plasma glucose</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

